DekaBank Deutsche Girozentrale’s Rubius Therapeutics, Inc RUBY Stock Holding History

DekaBank Deutsche Girozentrale’s Portfolio RUBY Stock Details RUBY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-31,900	Closed	-$174K	–	1434
2022 Q1	$174K	Buy	31,900 +2,900	+10%	+$18.4K	﹤0.01%	1230
2021 Q4	$289K	Buy	29,000 +800	+3%	+$11.1K	﹤0.01%	1205
2021 Q3	$490K	Hold	28,200	–	–	﹤0.01%	1050
2021 Q2	$659K	Hold	28,200	–	–	﹤0.01%	1005
2021 Q1	$703K	Hold	28,200	–	–	﹤0.01%	970
2020 Q4	$208K	Hold	28,200	–	–	﹤0.01%	1178
2020 Q3	$140K	Buy	+28,200	New	+$149K	﹤0.01%	1092
2019 Q1	–	Sell	-29,000	Closed	-$457K	–	1270
2018 Q4	$457K	Buy	+29,000	New	+$529K	﹤0.01%	844

Other funds holding RUBY

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AFM

Abbot Financial Management Andover, Massachusetts $239M AUM 27.19% 1-Year Est. Return

Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

DekaBank Deutsche Girozentrale's RUBY Position: Q2 2022 in Review

DekaBank Deutsche Girozentrale sold out of Rubius Therapeutics, Inc (RUBY) in Q2 2022, closing a stake of 31,900 shares — an estimated $174K sold.

DekaBank Deutsche Girozentrale first reported a position in RUBY in Q4 2018 and held it in 8 quarters. The position peaked at $703K in Q1 2021. 72 funds tracked by Wall St. Rank hold RUBY as of Q2 2022.

DekaBank Deutsche Girozentrale reported no remaining Rubius Therapeutics, Inc position as of Q2 2022 after selling out during the quarter.
DekaBank Deutsche Girozentrale sold 31,900 Rubius Therapeutics, Inc shares in Q2 2022, an estimated $174K.
DekaBank Deutsche Girozentrale first reported a position in Rubius Therapeutics, Inc in Q4 2018 and held it in 8 quarters.
DekaBank Deutsche Girozentrale's Rubius Therapeutics, Inc position peaked at $703K in Q1 2021.
72 funds tracked by Wall St. Rank held Rubius Therapeutics, Inc as of Q2 2022.

Based on DekaBank Deutsche Girozentrale's 13F filing for Q2 2022, filed 3 Aug 2022.